
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments is positioned for strong growth in the coming years, driven by its unique healthcare technology platform, Clover Assistant, which empowers Medicare physicians to proactively manage chronic diseases. The company's robust membership growth, with a strong base of returning members and high retention rates, is a testament to Clover's ability to profitably onboard new members in a competitive market. The company's focus on markets where it has a strong presence and high adoption of Clover Assistant, along with its strong financial performance and favorable rates, gives us confidence in Clover's ability to deliver in the future. However, there are potential risks, such as liquidity concerns, regulatory changes, and competition in the Medicare Advantage market, that could impact the company's financial performance. Overall, we believe Clover Health Investments has a solid foundation for sustained growth and profitability, and we maintain a positive outlook on the stock.
Bears say
Clover Health Investments is facing a combination of headwinds in 2027, including being paid as a 3.5-star plan and flat CMS MA advance rates. Management remains confident in its ability to manage medical costs through technology, but there is potential for negative surprises in these areas. Additionally, potential regulatory changes and competition could impact the company's profitability and outlook. While the company has shown impressive membership growth and profitability in 2025 and expects to achieve GAAP net income in 2026, there is still uncertainty surrounding its projections and potential risks.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares